Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering

Author's Avatar
Jul 19, 2019
Article's Main Image

SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $14.4 million before deducting underwriting discounts and commissions and offering expenses payable by Jaguar.